Efficacy, adherence and persistence of various glucagon‐like peptide‐1 agonists: nationwide real‐life data
Authors' conclusion
Weekly GLP-1RAs initiators were more adherent, persistent to therapy and achieved better glycaemic control. Epidemiological variables might play a role in achieving this goal.
Study context
- Population
- Adults with T2D who purchased any GLP-1RA between 2009 and 2021, Clalit Health Services electronic medical database; 51% females
- Participants
- 70,654 adults
- Exposure
- Once-weekly vs daily GLP-1RAs
- Outcome
- Percentage change in HbA1c
Methodological detailsnationwide, real-life data
- Nationwide
- Real-life data
Main finding
As reported in the abstract
Weekly GLP-1RA
14.6%
Daily
10.2%
P < 0.001
Observational data: associations, not effects.
Further findings
Any decrease in HbA1c
| Outcome | OR (95% CI) | |
|---|---|---|
| Good adherence (proportion of days covered ≥80%) | 1.25 (1.21–1.28) | |
| 0.512Odds ratio (log scale) |
- Any decrease in HbA1c — HbA1c reduction with semaglutide
- 16.0%
- Any decrease in HbA1c — HbA1c reduction with dulaglutide
- 14.7%
- Good adherence (proportion of days covered ≥80%) — Good adherence in older age, female gender, Jewish ethnicity and high socio-economic status
- p < 0.001
Original publication
Efficacy, adherence and persistence of various glucagon‐like peptide‐1 agonists: nationwide real‐life data. Diabetes Obes Metab. Published 7 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →